U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C30H32Cl3NO
Molecular Weight 528.94
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of LUMEFANTRINE

SMILES

CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C3=CC=C(Cl)C=C3\C2=C\C4=CC=C(Cl)C=C4

InChI

InChIKey=DYLGFOYVTXJFJP-MYYYXRDXSA-N
InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-

HIDE SMILES / InChI
Molecular Formula C30H32Cl3NO
Molecular Weight 528.94
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 1
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB06708 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7866ec19-dfac-47d4-a53f-511a12643cbf

Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy (Coartem tablets). Lumefantrine is a blood schizonticide active against erythrocytic stages of Plasmodium falciparum. The exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. The most common adverse reactions of Coartem in adults are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.

Originator

Academy of Military Medical Sciences
3
Curator's Comment: http://www.ncbi.nlm.nih.gov/pubmed/24650735

Approval Year

2009
359
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
COARTEM

Approved Use

Coartem (artemether/lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see Clinical Studies (14.1)

Launch Date

2009
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.2 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10681341/
480 mg 1 times / day multiple, oral
dose: 480 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LUMEFANTRINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
356 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10681341/
480 mg 1 times / day multiple, oral
dose: 480 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LUMEFANTRINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10681341/
480 mg 1 times / day multiple, oral
dose: 480 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LUMEFANTRINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.3%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10681341/
480 mg 1 times / day multiple, oral
dose: 480 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LUMEFANTRINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
240 mg 3 times / day multiple, oral
Recommended
Dose: 240 mg, 3 times / day
Route: oral
Route: multiple
Dose: 240 mg, 3 times / day
Co-administed with::
artemether(40 mg; PO; 4D1+2D2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A2403
unhealthy, 2
n = 310
Health Status: unhealthy
Condition: malaria
Age Group: 2
Sex: M+F
Population Size: 310
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A2403
Disc. AE: Urticaria...
AEs leading to
discontinuation/dose reduction:
Urticaria (grade 3-4)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A2403
480 mg 3 times / day multiple, oral
Recommended
Dose: 480 mg, 3 times / day
Route: oral
Route: multiple
Dose: 480 mg, 3 times / day
Co-administed with::
artemether(80 mg; PO; 4D1+2D2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A028
unhealthy, 25
n = 115
Health Status: unhealthy
Condition: malaria
Age Group: 25
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A028
Disc. AE: Abdominal pain...
Other AEs: Dyspnea, Pulmonary edema...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (grade 1-2, uncommon)
Other AEs:
Dyspnea (grade 3-4, uncommon)
Pulmonary edema (grade 3-4, uncommon)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A028
240 mg 3 times / day multiple, oral
Recommended
Dose: 240 mg, 3 times / day
Route: oral
Route: multiple
Dose: 240 mg, 3 times / day
Co-administed with::
artemether(40 mg; PO; 4D1+2D2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: B2303
unhealthy, 3
n = 447
Health Status: unhealthy
Condition: malaria
Age Group: 3
Sex: M+F
Population Size: 447
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: B2303
Disc. AE: Vomiting, Urticaria...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 3-4, most common)
Urticaria (grade 3-4)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: B2303
AEs

AEs

AESignificanceDosePopulation
Urticaria grade 3-4
Disc. AE
240 mg 3 times / day multiple, oral
Recommended
Dose: 240 mg, 3 times / day
Route: oral
Route: multiple
Dose: 240 mg, 3 times / day
Co-administed with::
artemether(40 mg; PO; 4D1+2D2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A2403
unhealthy, 2
n = 310
Health Status: unhealthy
Condition: malaria
Age Group: 2
Sex: M+F
Population Size: 310
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A2403
Abdominal pain grade 1-2, uncommon
Disc. AE
480 mg 3 times / day multiple, oral
Recommended
Dose: 480 mg, 3 times / day
Route: oral
Route: multiple
Dose: 480 mg, 3 times / day
Co-administed with::
artemether(80 mg; PO; 4D1+2D2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A028
unhealthy, 25
n = 115
Health Status: unhealthy
Condition: malaria
Age Group: 25
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A028
Dyspnea grade 3-4, uncommon
480 mg 3 times / day multiple, oral
Recommended
Dose: 480 mg, 3 times / day
Route: oral
Route: multiple
Dose: 480 mg, 3 times / day
Co-administed with::
artemether(80 mg; PO; 4D1+2D2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A028
unhealthy, 25
n = 115
Health Status: unhealthy
Condition: malaria
Age Group: 25
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A028
Pulmonary edema grade 3-4, uncommon
480 mg 3 times / day multiple, oral
Recommended
Dose: 480 mg, 3 times / day
Route: oral
Route: multiple
Dose: 480 mg, 3 times / day
Co-administed with::
artemether(80 mg; PO; 4D1+2D2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A028
unhealthy, 25
n = 115
Health Status: unhealthy
Condition: malaria
Age Group: 25
Sex: M+F
Population Size: 115
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: A028
Vomiting grade 3-4, most common
Disc. AE
240 mg 3 times / day multiple, oral
Recommended
Dose: 240 mg, 3 times / day
Route: oral
Route: multiple
Dose: 240 mg, 3 times / day
Co-administed with::
artemether(40 mg; PO; 4D1+2D2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: B2303
unhealthy, 3
n = 447
Health Status: unhealthy
Condition: malaria
Age Group: 3
Sex: M+F
Population Size: 447
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: B2303
Urticaria grade 3-4
Disc. AE
240 mg 3 times / day multiple, oral
Recommended
Dose: 240 mg, 3 times / day
Route: oral
Route: multiple
Dose: 240 mg, 3 times / day
Co-administed with::
artemether(40 mg; PO; 4D1+2D2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: B2303
unhealthy, 3
n = 447
Health Status: unhealthy
Condition: malaria
Age Group: 3
Sex: M+F
Population Size: 447
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Page: B2303
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737
inhibitor
1767

inducer
389
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2A6
707

CYP2C19
1478

CYP2E1
882

CYP3A4/5
278

CYP4A9/11
37
CYP1A2
701

CYP2B6
547

CYP2C8
168

CYP2C19
293

CYP3A
129

CYP1A1
108
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no [IC50 >2.0 uM]
CYP2A6
739
 no [IC50 >2.0 uM]
CYP2C19
1553
 no [IC50 >2.0 uM]
CYP2C9
1819
 no [IC50 >2.0 uM]
CYP2E1
970
 no [IC50 >2.0 uM]
CYP3A4/5
335
 no [IC50 >2.0 uM]
CYP4A9/11
37
 no [IC50 >2.0 uM]
CYP1A1
218
 no
CYP1A2
1692
 no
CYP2B6
1001
 no
CYP2C19
1553
 no
CYP2C8
965
 no
CYP2C9
1819
 no
CYP3A
298
 no
CYP2D6
1891
 yes [IC50 0.997 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1737
 major
yes (co-administration study)
Comment: Human liver microsomes, Recombinant CYP3A4; Modest changes (<2.5-fold increase) in systemic exposure were observed with inhibitors or substrates of CYP3A4 including ketoconazole, mefloquine or quinine. The concentrations seen in the ketoconazole drug interaction study were within the range of systemic concentrations of Coartem seen in malaria patients in Phase III efficacy and safety studies. The concurrent oral administration of ketoconazole (400 mg on Day 1 followed by 200 mg on days 2,3, 4 and 5) with co-artemether (single dose of 4 tablets of 20 mg artemether/120 mg lumefantrine) led to a modest increase in lumefantrine (1.3-fold (Cmax), 1.6-fold (AUClast)) exposure in healthy subjects.
Page: (ClinPharm) 7, 9, 11, 21, (PMDA_K100_1 in Japanese) 61
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
hERG
1647
DESBUYL-BENFLUMETOL
3
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-6299
http://www.3bsc.com/index/pro_info.php?id=116861
AA Blocks
AA0036I3
https://www.aablocks.com/goods/Goods/detail?id=AA0036I3
AK Scientific, Inc. (AKSCI)
65683
http://www.aksci.com/item_detail.php?cat=65683
Aaron Chemicals
AR00379V
http://www.aaronchem.com/82186-77-4
Achemo Scientific Limited
AC-74186
http://www.achemo.com/search/?Keyword= 82186-77-4
Achemtek
0104-019643
http://www.achemtek.com/82186-77-4
Acorn PharmaTech
ACN-048710
http://www.acornpharmatech.com/
Alfa Chemistry
AP82186774
https://reagents.alfa-chemistry.com/product/lumefantrine-cas-82186-77-4-16977.html
Alsachim
1354
http://www.alsachim.com/product-C1742-glo.bal-view.html
AstaTech, Inc.
24538
http://www.astatechinc.com/CPSResult.php?CRNO=27834
Aurum Pharmatech LLC
S-4170
http://www.Aurumpharmatech.com/Product/ProductDetails/S_4170
AvaChem Scientific
2433
http://www.avachem.com/productSearch.asp?2433
Avantor Inc
TCL0256-25G
https://us.vwr.com/store/product/16813025/lumefantrine-98-0-by-hplc-titration-analysis
Avantor Inc
TCL0256-5G
https://us.vwr.com/store/product/16813025/lumefantrine-98-0-by-hplc-titration-analysis
BLD Pharm
BD220185
http://www.bldpharm.com/products/204133-10-8.html
BLD Pharm
BD115323
http://www.bldpharm.com/products/82186-77-4.html
Boerchem
BC682501
http://www.boerchem.com/?product_40130.html
CSNpharm
CSN10394
https://www.csnpharm.com/products/lumefantrine.html
Chem Scene
CS-5130
http://www.chemscene.com/82186-77-4.html
ChemMol
30110287
http://www.chemmol.com/chemmol/30110287.html
ChemMol
44011083
http://www.chemmol.com/chemmol/44011083.html
ChemMol
49400258
http://www.chemmol.com/chemmol/49400258.html
ChemMol
99172515
http://www.chemmol.com/chemmol/99172515.html
Chemenu
CM110477
http://www.chemenu.com/products/CM110477
Chemspace
CSSB00016988937
https://chem-space.com/CSSB00016988937
Glentham Life Sciences
GP5101
http://www.glentham.com/products/product/GP5101/
Hairui
HR126098
http://www.hairuichem.com/en/product/82186-77-4.html
Lab Network
LN00175760
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00175760
Matrix Scientific
76072
https://www.matrixscientific.com/076072.html
MedChem Express
HY-B0803
https://www.medchemexpress.com/Lumefantrine.html
MuseChem
I004976
https://www.musechem.com/product/I004976.html
OChem
10386
http://www.ocheminc.com/index.php?act=psearch&pid=186L774
Oakwood
79421
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=64595&ExtHyperLink=1
Parchem
29326
http://www.parchem.com/chemical-supplier-distributor/Lumefantrine-019326.aspx
Renno Tech
RL05134
http://www.rennotech.com/product_show.asp?id=5383
Selleck Chemicals
S3746
http://www.selleckchem.com/products/lumefantrine.html
Sigma-Aldrich
L5420_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/l5420?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1370746_USP
https://www.sigmaaldrich.com/catalog/product/usp/1370746?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S533785
http://www.smolecule.com/products/s533785
Smolecule
S533786
http://www.smolecule.com/products/s533786
TCI (Tokyo Chemical Industry)
L0256
http://www.tcichemicals.com/eshop/en/us/commodity/L0256/index.html
THE BioTek
bt-274421
https://www.thebiotek.com/product/inhibitors/bt-274421
THE BioTek
bt-274423
https://www.thebiotek.com/product/inhibitors/bt-274423
VladaChem
VL279049-25G
https://www.vladachem.com/product.php?products=82186-77-4
Yuhao Chemical
SY0308
http://www.chemyuhao.com/82186-77-4.html
abcr GmbH
AB436173
http://www.abcr.com/shop/en/AB436173
eNovation Chemicals
D506030
https://www.enovationchem.com/ProductDetails.asp?ProductID=D506030
eNovation Chemicals
D674512
https://www.enovationchem.com/ProductDetails.asp?ProductID=D674512
eNovation Chemicals
D767145
https://www.enovationchem.com/ProductDetails.asp?ProductID=D767145
PubMed

PubMed

TitleDatePubMed
A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.
2013 Dec 17
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger.
2013 Jul
Synthesis and antimalarial efficacy of two-carbon-linked, artemisinin-derived trioxane dimers in combination with known antimalarial drugs.
2013 Mar 28
Breakdown of phosphatidylserine asymmetry following treatment of erythrocytes with lumefantrine.
2014 Feb 20
In vitro and in vivo combination of cepharanthine with anti-malarial drugs.
2014 Mar 12
Patents

Patents

JP2006503898A
44
JP2011524365A
34

Sample Use Guides

In Vivo Use Guide
Tablets should be administered over 3 days for a total of 6 doses: an initial dose, second dose after 8 hours and then twice-daily (morning and evening) for the following 2 days. The adult dosage for patients with bodyweight of 35 kg and above is 4 tablets per dose for a total of 6 doses. Tablets are scored and contain 20 mg rtemether and 120 mg lumefantrine.
Route of Administration: Oral
In Vitro Use Guide
IC90 is higher in Plasmodium falciparum strain T-996 compared with strain LS-21: for Lumefantrine 293.03 and 95.61 nmol/L (154.69 and 50.47 ng/ml of EMM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:27:25 GMT 2023
Edited
by admin
on Sat Dec 16 16:27:25 GMT 2023
Record UNII
F38R0JR742
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LUMEFANTRINE
DASH   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
LUMEFANTRINE COMPONENT OF COARTEM
Brand Name English
COARTEM COMPONENT LUMEFANTRINE
Brand Name English
LUMEFANTRINE [VANDF]
Common Name English
DL-BENFLUMELOL
Common Name English
LUMEFANTRINE [HSDB]
Common Name English
BENFLUMELOL
Common Name English
LUMEFANTRINUM [WHO-IP LATIN]
Common Name English
lumefantrine [INN]
Common Name English
GNF-PF-1971
Code English
LUMEFANTRINE [MART.]
Common Name English
9H-FLUORENE-4-METHANOL, 2,7-DICHLORO-9-((4-CHLOROPHENYL)METHYLENE)-.ALPHA.-((DIBUTYLAMINO)METHYL)-, (Z)-
Systematic Name English
LUMEFANTRINE [JAN]
Common Name English
LUMEFANTRINE [USP MONOGRAPH]
Common Name English
BENFLUMETOL
Common Name English
LUMEFANTRINE [MI]
Common Name English
LUMEFANTRINE [USAN]
Common Name English
(±)-2,7-DICHLORO-9-((Z)-P-CHLOROBENZYLIDENE)-.ALPHA.((DIBUTYLAMINO)METHYL)FLUORENE-4-METHANOL
Common Name English
CPG-56695
Code English
LUMEFANTRINE [USP-RS]
Common Name English
2-DIBUTYLAMINO-1-(2,7-DICHLORO-9-(1-(4-CHLOROPHENYL)METH-(Z)-YLIDENE)-9H-FLUOREN-4-YL)ETHANOL
Common Name English
Lumefantrine [WHO-DD]
Common Name English
LUMEFANTRINE [ORANGE BOOK]
Common Name English
LUMEFANTRINE [WHO-IP]
Common Name English
Classification Tree Code System Code
LIVERTOX 577
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
FDA ORPHAN DRUG 895622
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1 (ART/LUM)
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
NDF-RT N0000175482
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
WHO-ATC P01BF01
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
FDA ORPHAN DRUG 245507
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
EU-Orphan Drug EU/3/09/702
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
Code System Code Type Description
DRUG CENTRAL
1617
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
MERCK INDEX
m6927
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY Merck Index
HSDB
7210
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
NCI_THESAURUS
C81541
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
EVMPD
SUB08618MIG
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
FDA UNII
F38R0JR742
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
INN
7610
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
RS_ITEM_NUM
1370746
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
PUBCHEM
6437380
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
RXCUI
847728
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID3046663
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
CAS
204133-10-8
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
NON-SPECIFIC STEREOCHEMISTRY
ChEMBL
CHEMBL422330
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
MESH
C102070
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
USAN
UU-174
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
WIKIPEDIA
Lumefantrine
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
CAS
120583-69-9
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
SUPERSEDED
LACTMED
Artemether and Lumefantrine
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
DAILYMED
F38R0JR742
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
SMS_ID
100000091055
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
DRUG BANK
DB06708
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
CAS
82186-77-4
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
CHEBI
156095
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
LUMEFANTRINE
Created by admin on Sat Dec 16 16:27:27 GMT 2023 , Edited by admin on Sat Dec 16 16:27:27 GMT 2023
PRIMARY Description: A yellow crystalline powder.Solubility: Practically insoluble in water; soluble in dichloromethane R; slightly soluble in methanol R .Category: Antimalarial.Storage: Lumefantrine should be kept in a well-closed container.Additional information. Lumefantrine melts at 128?132?C.Definition: Lumefantrine contains not less than 98.5% and not more than 101.0% of C30H32Cl3NO, calculated with reference to the dried substance.
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Structure of LUMEFANTRINE, (+)-
ENANTIOMER -> RACEMATE
CYTOCHROME P450 2D6
METABOLIC ENZYME -> INHIBITOR
In vitro, lumefantrine significantly inhibits the activity of CYP2D6 at therapeutic plasma concentrations
Structure of LUMEFANTRINE, (-)-
ENANTIOMER -> RACEMATE
Plasmodium falciparum
TARGET ORGANISM->INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of DESBUTYL LUMEFANTRINE
METABOLITE -> PARENT
In human liver microsomes and in recombinant CYP450 enzymes, lumefantrine was metabolized mainly by CYP3A4 to desbutyl-lumefantrine
PLASMA
Related Record Type Details
Structure of 2-(DIBUTYLAMINO)-2-(2,7-DICHLORO-9-(4-CHLOROBENZYLIDENE)-9H-FLUOREN-4-YL)ETHANOL, (Z)-
IMPURITY -> PARENT
Structure of DESBUTYL LUMEFANTRINE
IMPURITY -> PARENT
Structure of 2-(DIBUTYLAMINO)-2-(2,7-DICHLORO-9-(4-CHLOROBENZYLIDENE)-9H-FLUOREN-4-YL)ETHANOL, (Z)-
IMPURITY -> PARENT
LUMEFANTRINE Impurity A. The impurity peaks are eluted at the following relative retention with reference to lumefantrine (retention time about 10 minutes): impurity A about 0.9.
Related Record Type Details
Structure of LUMEFANTRINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC in patients with P. falciparum malaria

Biological Half-life PHARMACOKINETIC in healthy volunteers

Tmax PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966